Summary of findings table ‐ Continuation vs reduction of polypharmacy
Quality of life: clinically important change ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
- Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia 2022 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found